The TriMix therapy consists of a combination of mRNA encoding three distinct immune-stimulating proteins, namely CD40 ligand (CD40L), CD70, and constitutively active TLR4.276 This innovative mRNA-based vaccine can be administered via intratumoral injection for patients with early-stage, resectable breast cancer, which is currently undergoing Phase I clinical trial (NCT03788083). Here, CD40LG is linked to breast carcinoma.